查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1404654

再生醫學市場規模、佔有率、趨勢分析報告：按產品、治療類別、地區、細分市場預測，2024-2030

Regenerative Medicine Market Size, Share & Trends Analysis Report By Product, By Therapeutic Category, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 230 Pages | 商品交期: 2-10個工作天內

價格

再生醫學市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計2024年至2030年全球再生醫學市場規模將以16.79%的複合年成長率擴張，2030年將達到900.1億美元。

強大的產品線是再生醫學市場的關鍵促進因素之一。本公司大力投資研發，利用最新技術升級產品，滿足客戶未滿足的需求。

此外，對疾病治療療法的需求不斷成長，促使公司專注於加速在基因組層面上針對疾病原因的基因療法的研究和開發。根據PhRMA發表的資料，美國處於管道計畫（I-III期試驗）的細胞和基因治療藥物數量從2018年的289個增加到2019年的362個。這是一年內成長了 25%。該領域的持續進步可能會進一步推動再生醫學的需求。

幹細胞、組織工程和奈米技術等技術的進步使再生醫學成為一個高度跨學科的領域。幹細胞是未分化的細胞，具有修復和再生其他細胞（如軟骨、肌腱、韌帶、肌肉和骨骼）的能力。 2021 年 7 月，BlueRock Therapeutics 的 DA01 獲得 FDA核准，DA01 是一種多功能細胞衍生的多巴胺能神經元療法，用於治療進行性帕金森氏症。此次核准預計將擴大該公司的產品陣容。

幾家主要企業正在採取新產品開發和策略聯盟等策略性舉措，為再生醫學市場的成長做出貢獻。例如，2021年11月，Astellas製藥與Pantherna Therapeutics GmbH簽署了一項協議，研究基於mRNA的再生醫學。該計劃利用Astellas的藥物藥物研發能力和 Pantherna 的尖端 mRNA 平台來推動研究開發新項目。此外，2021 年 5 月，拜耳股份公司與 Senti Bio 建立合作夥伴關係，開發結合遺傳電路的再生醫學細胞療法。

再生醫學市場報告亮點

  • 由於社會高齡化和與老齡化的疾病增加，治療藥物領域佔據了再生醫學市場的最大佔有率。
  • 幹細胞和組織再生療法臨床試驗的增加以及再生療法需求的增加預計將對市場成長產生積極影響。
  • 由於研發方面的巨額投資以及幹細胞庫的擴散，基於幹細胞和前驅細胞細胞的治療方法有望顯著成長。
  • 2023年的市場規模以北美為主，因為有許多研究機構和大學致力於幹細胞治療方法的研發。
  • 由於細胞技術在醫療保健行業的快速採用，預計亞太地區在未來幾年將經歷最快的成長。
  • 從治療類別來看，隨著全球癌症患者數量的增加，對更好解決方案的需求增加，腫瘤學將在 2023 年佔據該領域的主導地位。強勁的管道增加正在推動市場成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場趨勢及展望
  • 市場動態
    • 擁有強大的產品線和大量的臨床試驗
    • 再生醫學的高經濟效益
    • 基因治療在再生醫學的新應用
    • 增加政府和私人資金支持再生醫學的發展
    • 再生醫學的技術進步（幹細胞、組織工程、奈米技術）
    • 加強策略夥伴關係，加速再生醫學的開發與商業化
    • 慢性病、遺傳疾病、退化性疾病疾病以及骨關節疾病盛行率的上升將增加對再生治療的需求
  • 市場抑制因素分析
    • 昂貴的治療費用
    • 與幹細胞、組織工程和再生醫學相關的監管問題
  • 營商環境分析
    • PESTEL分析
    • 波特五力分析
    • COVID-19感染疾病的影響分析

第4章 產品經營分析

  • 全球再生醫學市場：產品波動分析
  • 療法
    • 治療藥物市場，2018-2030
    • 初代細胞治療方法
    • 基於幹細胞和前驅細胞的治療方法
    • 基於細胞的免疫療法
    • 基因治療
  • 工具
    • 工具市場，2018-2030
  • 銀行
    • 銀行市場，2018-2030
  • 服務
    • 服務市場，2018-2030

第5章治療類別業務分析

  • 全球再生醫學市場：治療類別變化分析
  • 皮膚科
  • 肌肉骨骼系統
  • 免疫學和發炎
  • 腫瘤學
  • 心血管
  • 眼科
  • 其他

第6章 區域業務分析

  • 2022年及2030年全球再生醫學市場佔有率（按地區）
  • 北美洲
    • 北美再生醫學市場，2018-2030
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲再生醫學市場，2018-2030
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 亞太再生醫學市場，2018-2030
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 拉丁美洲再生醫學市場，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 中東和非洲再生醫學市場，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章競爭形勢

  • 公司分類
  • 策略規劃
  • 2022 年公司市場/職位佔有率分析
  • 公司簡介/名單
    • AstraZeneca plc.
    • F. Hoffmann-La Roche Ltd.
    • Integra Lifesciences Corp.
    • Astellas Pharma, Inc.
    • Cook Biotech, Inc.
    • Bayer AG
    • Pfizer, Inc.
    • Merck KGaA
    • Abbott
    • Vericel Corp.
    • Novartis AG
    • GlaxoSmithKline
Product Code: GVR-1-68038-952-4

Regenerative Medicine Market Growth & Trends:

The global regenerative medicine market size is expected to reach USD 90.01 billion by 2030, expanding at a CAGR of 16.79% from 2024 to 2030, according to a new report by Grand View Research, Inc. The presence of a strong pipeline is one of the major drivers in the regenerative medicine market. Companies invest heavily in R&D to upgrade their products with the latest technology and fulfil the unmet needs of their customers.

Furthermore, with the increasing demand for disease treatment therapies, companies have focused their efforts to accelerate R&D for gene therapies that target the cause of disease at a genomic level. The cell and gene therapies in the U.S. pipeline programs (Phase I-III trials) grew from 289 in 2018 to 362 by 2019 according to the data published by PhRMA,. This represents an increase of 25% in a single year. Continuous advancements in this field would further boost the demand for regenerative medicines.

Technological advancements such as stem cells, tissue engineering, and nanotechnology has made regenerative medicines a highly interdisciplinary in field. Stem cells are undifferentiated cells, which have the capability to repair and/or regenerate into other cells such as cartilage, tendons, ligaments, muscle, and bones. In July 2021, BlueRock Therapeutics received FDA approval for its pluripotent stem cell-derived dopaminergic neuron therapy, DA01, for advanced Parkinson's disease treatment. This approval was expected to expand the company's offerings.

Several key players are taking strategic initiatives such as new product development, strategic alliances, and others have contributed to the regenerative medicine market growth. For instance, in November 2021, Astellas Pharma, Inc. entered into an agreement with Pantherna Therapeutics GmbH to study mRNA-based regenerative medicine. Under this initiative, Astellas' high drug discovery capabilities and Pantherna's state-of-the-art mRNA platform will be used to promote research on developing a new program. In addition, in May 2021, Bayer AG entered into a collaboration with Senti Bio for gene circuit-engineered cell therapies development for regenerative medicine.

Regenerative Medicine Market Report Highlights:

  • The therapeutics segment held the largest share in the regenerative medicine market, owing to the growing aging population coupled with an increasing rate of age-related disorders.
  • The rise in a number of clinical trials for stem cell and tissue-based regenerative therapies along with an increase in demand for regenerative therapies is expected to positively influence the growth of the market.
  • Stem cell and progenitor cell-based therapies are projected to witness significant growth owing to huge investments in the R&D space and a growing number of stem cell banks
  • North America dominated the market in 2023 owing to the presence of a significant number of research organizations and universities which are working on R&D of stem cell-based therapies.
  • Asia Pacific is anticipated to witness the fastest growth in the coming years owing to the rapid adoption of cell-based methods in the healthcare industry.
  • By therapeutic category, the oncology segment dominated the segment in 2023 owing to the increasing cases of cancer globally which is rising the demand for better solutions. The growing number of robust pipelines is driving the market growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Information analysis
    • 1.2.2. Market formulation & data visualization
    • 1.2.3. Data validation & publishing
  • 1.3. Information Procurement
    • 1.3.1. Primary Others
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Market Model
  • 1.7. Objectives
    • 1.7.1. Objective 1
    • 1.7.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Presence of a strong pipeline and a large number of clinical trials
    • 3.3.2. High economic impact of regenerative medicine
    • 3.3.3. Emerging applications of gene therapy in regenerative medicine
    • 3.3.4. Increasing government & private funding to support the development of regenerative medicine
    • 3.3.5. Technological advancements in regenerative medicine (stem cell, tissue engineering, and nanotechnology)
    • 3.3.6. Increase in strategic partnerships to accelerate development & commercialization of regenerative medicines
    • 3.3.7. Rising prevalence of chronic diseases & genetic disorders, degenerative diseases, and bone & joint diseases leading to rise in demand for regenerative treatments
  • 3.4. Market Restraint Analysis
    • 3.4.1. High cost of treatment
    • 3.4.2. Regulatory issues pertaining to stem cells, tissues engineering, and regenerative medicines
  • 3.5. Business Environment Analysis
    • 3.5.1. PESTEL Analysis
    • 3.5.2. Porter's Five Forces Analysis
    • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

  • 4.1. Global Regenerative Medicine Market: Product Movement Analysis
  • 4.2. Therapeutics
    • 4.2.1. Therapeutics Market, 2018 - 2030 (USD Million)
    • 4.2.2. Primary Cell-Based Therapeutics
      • 4.2.2.1. Primary Cell-Based Therapeutics Market, 2018 - 2030 (USD Million)
      • 4.2.2.2. Dermatology
      • 4.2.2.2.1. Dermatology Market, 2018 - 2030 (USD Million)
      • 4.2.2.3. Musculoskeletal
      • 4.2.2.3.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
      • 4.2.2.4. Surgical
      • 4.2.2.4.1. Surgical Market, 2018 - 2030 (USD Million)
      • 4.2.2.5. Dental
      • 4.2.2.5.1. Dental Market, 2018 - 2030 (USD Million)
      • 4.2.2.6. Others
      • 4.2.2.6.1. Others Market, 2018 - 2030 (USD Million)
    • 4.2.3. Stem Cell & Progenitor Cell-based therapeutics
      • 4.2.3.1. Stem Cell & Progenitor Cell-based therapeutics Market, 2018 - 2030 (USD Million)
      • 4.2.3.2. Autologous
      • 4.2.3.2.1. Autologous Market, 2018 - 2030 (USD Million)
      • 4.2.3.3. Allogenic
      • 4.2.3.3.1. Allogenic Market, 2018 - 2030 (USD Million)
      • 4.2.3.4. Others
      • 4.2.3.5. Others Market, 2018 - 2030 (USD Million)
    • 4.2.4. Cell-based Immunotherapies
      • 4.2.4.1. Cell-based Immunotherapies Market, 2018 - 2030 (USD Million)
    • 4.2.5. Gene Therapies
      • 4.2.5.1. Gene Therapies Market, 2018 - 2030 (USD Million)
  • 4.3. Tools
    • 4.3.1. Tools Market, 2018 - 2030 (USD Million)
  • 4.4. Banks
    • 4.4.1. Banks Market, 2018 - 2030 (USD Million)
  • 4.5. Services
    • 4.5.1. Services Market, 2018 - 2030 (USD Million)

Chapter 5. Therapeutic Category Business Analysis

  • 5.1. Global Regenerative Medicine Market: Therapeutic Category Movement Analysis
  • 5.2. Dermatology
    • 5.2.1. Dermatology Market, 2018 - 2030 (USD Million)
  • 5.3. Musculoskeletal
    • 5.3.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
  • 5.4. Immunology & Inflammation
    • 5.4.1. Immunology & Inflammation Market, 2018 - 2030 (USD Million)
  • 5.5. Oncology
    • 5.5.1. Oncology Market, 2018 - 2030 (USD Million)
  • 5.6. Cardiovascular
    • 5.6.1. Cardiovascular Market, 2018 - 2030 (USD Million)
  • 5.7. Ophthalmology
    • 5.7.1. Ophthalmology Market, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Global Regenerative Medicine Market Share By Region, 2022 & 2030
  • 6.2. North America
    • 6.2.1. North America Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. Key Country Dynamics
      • 6.2.2.2. Competitive Scenario
      • 6.2.2.3. Regulatory Framework
      • 6.2.2.4. Target Disease Prevalence
      • 6.2.2.5. U.S. Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Competitive Scenario
      • 6.2.3.3. Regulatory Framework
      • 6.2.3.4. Target Disease Prevalence
      • 6.2.3.5. Canada Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.2. Germany
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Competitive Scenario
      • 6.3.2.3. Regulatory Framework
      • 6.3.2.4. Target Disease Prevalence
      • 6.3.2.5. Germany Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.3. UK
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Competitive Scenario
      • 6.3.3.3. Regulatory Framework
      • 6.3.3.4. Target Disease Prevalence
      • 6.3.3.5. UK Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Competitive Scenario
      • 6.3.4.3. Regulatory Framework
      • 6.3.4.4. Target Disease Prevalence
      • 6.3.4.5. France Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Competitive Scenario
      • 6.3.5.3. Regulatory Framework
      • 6.3.5.4. Target Disease Prevalence
      • 6.3.5.5. Italy Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Competitive Scenario
      • 6.3.6.3. Regulatory Framework
      • 6.3.6.4. Target Disease Prevalence
      • 6.3.6.5. Spain Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Competitive Scenario
      • 6.3.7.3. Regulatory Framework
      • 6.3.7.4. Target Disease Prevalence
      • 6.3.7.5. Denmark Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Competitive Scenario
      • 6.3.8.3. Regulatory Framework
      • 6.3.8.4. Target Disease Prevalence
      • 6.3.8.5. Sweden Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Competitive Scenario
      • 6.3.9.3. Regulatory Framework
      • 6.3.9.4. Target Disease Prevalence
      • 6.3.9.5. Norway Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Competitive Scenario
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Target Disease Prevalence
      • 6.4.2.5. Japan Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Competitive Scenario
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Target Disease Prevalence
      • 6.4.3.5. China Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Competitive Scenario
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Target Disease Prevalence
      • 6.4.4.5. India Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Competitive Scenario
      • 6.4.5.3. Regulatory Framework
      • 6.4.5.4. Target Disease Prevalence
      • 6.4.5.5. South Korea Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Competitive Scenario
      • 6.4.6.3. Regulatory Framework
      • 6.4.6.4. Target Disease Prevalence
      • 6.4.6.5. Australia Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Competitive Scenario
      • 6.4.7.3. Regulatory Framework
      • 6.4.7.4. Target Disease Prevalence
      • 6.4.7.5. Thailand Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Target Disease Prevalence
      • 6.5.2.5. Brazil Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Target Disease Prevalence
      • 6.5.3.5. Mexico Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.5.4. Argentina
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Competitive Scenario
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Target Disease Prevalence
      • 6.5.4.5. Argentina Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.6. MEA
    • 6.6.1. MEA Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Target Disease Prevalence
      • 6.6.2.5. South Africa Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Target Disease Prevalence
      • 6.6.3.5. Saudi Arabia Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Target Disease Prevalence
      • 6.6.4.5. UAE Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Competitive Scenario
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Target Disease Prevalence
      • 6.6.5.5. Kuwait Regenerative Medicine Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market/Position Share Analysis, 2022
  • 7.4. Company Profiles/Listing
    • 7.4.1. AstraZeneca plc.
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. F. Hoffmann-La Roche Ltd.
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Integra Lifesciences Corp.
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Astellas Pharma, Inc.
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Cook Biotech, Inc.
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. Bayer AG
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Pfizer, Inc.
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Merck KGaA
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Abbott
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Vericel Corp.
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives
    • 7.4.11. Novartis AG
      • 7.4.11.1. Overview
      • 7.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.11.3. Product Benchmarking
      • 7.4.11.4. Strategic Initiatives
    • 7.4.12. GlaxoSmithKline
      • 7.4.12.1. Overview
      • 7.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.12.3. Product Benchmarking
      • 7.4.12.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviations
  • Table 3 Global Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 4 Global Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 5 North America Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
  • Table 6 North America Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 7 North America Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 8 U.S. Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 9 U.S. Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 10 Canada Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 11 Canada Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 12 Europe Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
  • Table 13 Europe Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 14 Europe Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 15 Germany Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 16 Germany Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 17 U.K. Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 18 U.K. Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 19 France Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 20 France Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 21 Italy Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 22 Italy Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 23 Spain Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 24 Spain Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 25 Denmark Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 26 Denmark Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 27 Norway Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 28 Norway Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 29 Sweden Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 30 Sweden Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 34 China Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 35 China Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 36 Japan Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 37 Japan Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 38 India Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 39 India Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 40 Australia Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 41 Australia Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 42 South Korea Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 43 South Korea Regenerative Medicine Market, by services, 2018 - 2030 (USD Million)
  • Table 44 Thailand Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 45 Thailand Regenerative Medicine Market, by services, 2018 - 2030 (USD Million)
  • Table 46 Latin America Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
  • Table 47 Latin America Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 48 Latin America Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 49 Brazil Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 50 Brazil Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 51 Mexico Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 52 Mexico Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 53 Argentina Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 54 Argentina Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 58 South Africa Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 59 South Africa Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 62 UAE Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 63 UAE Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 64 Kuwait Regenerative Medicine Market, by product, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Regenerative Medicine Market, by therapeutic category, 2018 - 2030 (USD Million)
  • Table 66 Participant's Overview
  • Table 67 Financial Performance
  • Table 68 Key Companies Undergoing Expansions
  • Table 69 Key Companies Undergoing Acquisitions
  • Table 70 Key Companies Undergoing Collaborations
  • Table 71 Key Companies Launching New Products/Services
  • Table 72 Key Companies Undergoing Partnerships
  • Table 73 Key Companies Undertaking Other Strategies

List of Figures

  • Fig. 1 Market Others process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary Others pattern
  • Fig. 4 Market Others approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market summary, 2023 (USD Million)
  • Fig. 9 Market segmentation & scope
  • Fig. 10 Market driver impact
  • Fig. 11 Market restraint impact
  • Fig. 12 Penetration & growth prospect mapping
  • Fig. 13 Porter's analysis
  • Fig. 14 SWOT analysis
  • Fig. 15 Global regenerative medicine therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 16 Global primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 17 Global dermatology primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 18 Global musculoskeletal primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 19 Global surgical primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 20 Global dental primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 21 Global other primary cell-based therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 22 Global autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 23 Global autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 24 Global allogeneic stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 25 Global other stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 26 Global cell-based immunotherapies market, 2018 - 2030 (USD Million)
  • Fig. 27 Global gene therapies market, 2018 - 2030 (USD Million)
  • Fig. 28 Global regenerative medicines tools, 2018 - 2030 (USD Million)
  • Fig. 29 Global banks market for regenerative medicine, 2018 - 2030 (USD Million)
  • Fig. 30 Global regenerative medicine services market, 2018 - 2030 (USD Million)
  • Fig. 31 Regenerative medicine market: Therapeutic category outlook and key takeaways
  • Fig. 32 Regenerative medicine market: Therapeutic category movement analysis (USD Million)
  • Fig. 33 Global dermatological therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 34 Global musculoskeletal therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 35 Global immunology & inflammation therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 36 Global oncology therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 37 Global cardiovascular therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 38 Global ophthalmology therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 39 Global other therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 40 Global Regenerative Medicine Market: Regional outlook and key takeaways
  • Fig. 41 North America Regenerative Medicine Market, 2018 - 2030 (USD million)
  • Fig. 42 U.S. key country dynamics
  • Fig. 43 U.S. Regenerative Medicine Market, 2018 - 2030 (USD million)
  • Fig. 44 Canada key country dynamics
  • Fig. 45 Canada Regenerative Medicine Market, 2018 - 2030 (USD million)
  • Fig. 46 Europe Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Germany key country dynamics
  • Fig. 48 Germany Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 France key country dynamics
  • Fig. 50 France Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 U.K. key country dynamics
  • Fig. 52 U.K. Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Italy key country dynamics
  • Fig. 54 Italy Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Spain key country dynamics
  • Fig. 56 Spain Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Denmark key country dynamics
  • Fig. 58 Denmark Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Sweden key country dynamics
  • Fig. 60 Sweden Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Norway key country dynamics
  • Fig. 62 Norway Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Asia-Pacific Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 China key country dynamics
  • Fig. 65 China Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 India key country dynamics
  • Fig. 67 India Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 South Korea key country dynamics
  • Fig. 69 South Korea Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Japan key country dynamics
  • Fig. 71 Japan Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Australia key country dynamics
  • Fig. 73 Australia Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Thailand key country dynamics
  • Fig. 75 Thailand Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 76 Latin America Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 77 Brazil key country dynamics
  • Fig. 78 Brazil Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 Mexico key country dynamics
  • Fig. 80 Mexico Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 Argentina key country dynamics
  • Fig. 82 Argentina Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 MEA Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 84 South Africa key country dynamics
  • Fig. 85 South Africa Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 86 Saudi Arabia key country dynamics
  • Fig. 87 Saudi Arabia Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 UAE key country dynamics
  • Fig. 89 UAE Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 90 Kuwait key country dynamics
  • Fig. 91 Kuwait Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 92 Market participant categorization
  • Fig. 93 Regenerative Medicine Market share analysis, 2023
  • Fig. 94 Strategy framework